Nurse Anesthetist - CR in Prescott, AZ Accepting Medicare
3 Nurse Anesthetist - CR nurses found. Showing 1 - 3
 Mr. Scott Allan Jolliffe, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 5430 Distinction Way, Prescott, AZ 86301 Phone: 928-445-1919 |
 Cynthia D Bolena, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1600 Willow Creek Rd, Prescott, AZ 86301 Phone: 928-776-7477 Fax: 928-776-0693 |
Jagjit Singh Sandhu, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 815 Ainsworth Dr, Prescott, AZ 86301 Phone: 928-533-7234 |
News Archive
Study: Life-long antiviral treatment appears to prevent viral transmission from mother to baby
Anti-retroviral drugs are a vital tool in the prevention and treatment of HIV. A new study of pregnant women in Tanzania shows that life-long antiviral treatment also seems to prevent viral transmission from mother to baby.
MEPs organizes joint meeting to improve policies for tackling chronic diseases
In an unprecedented effort to bring prevention of chronic diseases to the top of the EU agenda, the MEP Heart Group , the MEP Group for Kidney Health , the EU Diabetes Working Group and MEPs Against Cancer organise a joint meeting today in the European Parliament, together with representatives of health professionals and health activists at European level.
New squeeze test for screening potential drugs for Alzheimer's
Brain cells exposed to a form of the amyloid beta protein, the molecule linked to Alzheimer's disease, become stiffer and bend less under pressure, researchers at UC Davis have found. The results reveal one mechanism by which the amyloid protein damages the brain, a finding that could lead to new ways to screen drugs for Alzheimer's and similar diseases.
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven
The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment.
Genetic markers may predict tumor samples that respond to treatment
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
› Verified 8 days ago